Human papillomaviruses and cervical neoplasia: A model for carcinogenesis

International Journal of Gynecological Pathology

Volumn 19, Issue 1, 2000, Pages 16-28

  Stoler, Mark H ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Cancer; Cervix; HPV; Papillomavirus; Pathogenesis; Screening

Indexed keywords

VIRUS DNA; VIRUS VACCINE;

CANCER INHIBITION; CANCER SCREENING; FEMALE; HUMAN; HUMAN TISSUE; PRECANCER; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; VACCINE PRODUCTION; VIRUS CARCINOGENESIS; VIRUS ONCOGENE; WART VIRUS;

EID: 0033988341     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-200001000-00004     Document Type: Review

References (167)

1. Shope RE, Hurst EW. Infectious papillomatosis of rabbits: with a note on thé histopathology. J Exp Med 1933;58:607-24.
2. Rous P, Kidd JG. The carcinogenic effect of a virus on tarred skin. Science 1936;83:468-9.
3. Kidd JG, Rous P. A transplantable rabbit carcinoma orginating in a virus induced papilloma and containing the virus in masked or altered form. / Exp Med 1940;71:813-37.
4. Blank H, Davis C, Collins C. Electron microscopy for the diagnosis of cutaneous viral infections. Br J Dermatol 1970; 83(Suppl.):69-80.
5. Boyle WF, Riggs JL, Oshiro LS, Lennette EH. Electron microscopic identification of papova virus in laryngeal papilloma. Laryngoscope 1973;83:1102-8.
6. Hills E, Laverty CR. Electron microscopic detection of papilloma virus particles in selected koilocytotic cells in a routine cervical smear. Acta Cytol 1979;23:53-6.
7. Smith J, Coleman DV. Electron microscopy of cells showing viral cytopathic effects in Papanicolaou smears. Acta Cytol 1983;27: 605-13.
8. Rowson KEK, Mahy BWJ. Human papova (wart) virus infection. Bacterial Rev 1967;31:110-31.
9. Gissmann L, Pfister H, zur Hausen H. Human papilloma viruses (HPV): characterization of four different isolates. Virology 1977; 76:569-80.
10. Gissmann L, deVilliers EM, zur Hausen H. Analysis of human genital warts (condylomata acuminata) and other genital tumors for human papillomavirus type 6 DMA. Int J Cancer 1982;29: 143-6.
11. de Villiers EM. Human pathogenic papillomavirus types: an update. Curr Top Microbiol Immunol 1994;186:1-12.
12. de Villiers EM. Papillomavirus and HPV typing. Clin Dermatol 1997;15:199-206.
13. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988;10:12263.
14. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
15. Howley PM. Papillomaviruses and their replication. In: Field BN, Knipe DM, eds. Field's Virology, 3rd. ed. New York: Raven Press; 1995:947-79.
16. Van Ranst M, Kaplan JB, Burk RD. Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations. J Gen Virol 1992;73:2653-60.
17. Van Ranst MA, Tachezy R, Delius H, Burk RD. Taxonomy of the human papillomaviruses. Papillomavirus Report 1993;3:61-5.
18. Ho GY, Burk RD, Fleming I, Klein RS. Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression. Int J Cancer 1994;56:78892.
19. Bernard HU. Coevolution of papillomaviruses with human populations. Trends Microbiol 1994;2:140-3.
20. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992;79:328-37.
21. Wilbur DC, Reichman RC, Stoler MH. Detection of infection by human papillomavirus in genital condylomata: a comparison study using immunocytochemistry and in situ nucleic acid hybridization. Am J Clin Pathol 1988;89:505-10.
22. Munoz N, Bosch FX, Shah KV, Meheus A, eds. The Epidemiology of Human Papillomavirus and Cervical Cancer. New York: Oxford University Press; 1992.
23. Munoz N, Bosch FX. The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer. Bull Pan Am Health Organ 1996;30:362-77.
24. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologie evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia [see Comments]. J Natl Cancer Inst 1993;85:958-64.
25. Schiffman MH. Epidemiology of cervical human papillomavirus infections. Curr Top Microbiol Immunol 1994;186:55-81.
26. Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer 1995;76(10 Suppl):1888-901.
27. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation of papillomavirus infection. N Engl J Med 1992;327:1272-8.
28. Sherman ME, Schiffman MH, Lorincz AT, et al. Toward objective quality assurance in cervical cytopathology: correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol 1994;102:182-7.
29. de Villiers E, Wagner D, Schneider A, et al. Human papillomavirus DNA in women without and with cytological abnormalities: results of a 5-year follow-up study. Gynecol Oncol 1992;44:33-9.
30. Bauer HM, Ting Y, Gréer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method [see comments]. JAMA 1991;265:472-7.
31. Bauer HM, Hildesheim A, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 1993;20:274-8.
32. Schneider A, Kirchhoff T, Meinhardt G, Gissmann L. Repeated evaluation of human papillomavirus 16 status in cervical swabs of young women with a history of normal Papanicolaou smears. Obstet Gynecol 1992;79:683-8.
33. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169:235-0.
34. Nasiell K, Nasiell M, Vaclavinkova V. Behavior of moderate cervical dysplasia during long-term follow-up. Obstet Gynecol 1983;61:609-14.
35. Nasiell K, Roger B, Nasiell M. Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol 1986;67: 665-9.
36. Patten SF. Diagnostic Cytopathology of the Uterine Cervix. 2nd ed. Basel: Karger; 1978.
37. Syrjanen K, Mantyjarvi R, Saarikoski S, et al. Factors associated with progression of cervical human papillomavirus (HPV) infections into carcinoma in situ during a long-term prospective follow-up. Bri J Obstet Gynaecol 1988;95:1096-102.
38. Syrjanen K, Hakama M, Saarikoski S, et al. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex TransmDis 1990;17:15-9.
39. Syrjanen K, Kataja V, Yliskoski M, Chang F, Syrjanen S, Saarikoski S. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol 1992;79:675-82.
40. Koss LG, Durfee GR. Unusual patterns of squamous epithelium of the uterine cervix: cytologie and pathologic study of koilocytotic atypia. Ann NY Acad Sei 1956;63:1245-1261.
41. Meisels A, Morin C, Casas CM, Rabreau M. Human papillomavirus (HPV) venereal functions and gynecologic cancer. Palhol Anna 1983;2:277-93.
42. Winkler B, Crum CP, Fujii T, et al. Koilocytotic lesions of the cervix: the relationship of mitotic abnormalities to the presence of papillomavirus antigens and nuclear DNA content. Cancer 1984; 53:1081-7.
43. Meisels A, Fortin R. Condylomatous lesions of the cervix and vagina. I. Cytologie patterns. Acta Cytol 1976;20:505-9.
44. Meisels A. The story of a cell. The George N. Papanicolaou Award lecture. Acta Cytol 1983;27:584-96.
45. Purola E, Savia E. Cytology of gynecologic condyloma acuminatum. Acta Cytol 1977;21:26-31.
46. Kurman RJ, Shah KH, Lancaster WD, Jenson AB. Immunoperoxidase localization of papillomavirus antigens in cervical dysplasia and vulvar condylomas. Am J Obstet Gynecol 1981;140: 931-5.
47. Kurman RJ, Sanz LE, Jenson AB, Perry S, Lancaster WD. Papillomavirus infections of the cervix. I. Correlation of histology with viral structural antigens and DNA sequences. Int J Gynecol Pathol 1982;l:17-28.
48. Kurman RJ, Jenson AB, Lancaster WD. Papillomavirus infection of the cervix. II. Relationship to intraepithelial neoplasia based on the presence of specific viral structural proteins. Am J Surg Pathol 1983;7:39-52.
49. Laverty C. Noncondylomatous wart virus infection of the cervix: cytologie, histologie and electronmicroscopic features. Obstet Gynecol Surv 1979;34:820-2.
50. Sato S, Okagaki T, Clark BA, et al. Sensitivity of koilocytosis, immunocytochemistry, and electron microscopy as compared to DNA hybridization in detecting human papillomavirus in cervical and vaginal condyloma and intraepithelial neoplasia. Int J Gynecol Pathol 1986;5:297-307.
51. Toki T, Oikawa N, Tase T, et al. Immunohistochemical and electron microscopic demonstration of human papillomavirus in dysplasia of the uterine cervix. Tohoku J Exp Aled 1986:149:163-7.
52. Lorincz A. The detection of genital human papillomavirus infection using polymerase chain reaction [Letter; Comment]. 7AMA 1991:265:2809-10.
53. Lorincz AT. Detection of human papillomavirus infection by nucleic acid hybridization. Obstet Gynecol Clin North Am 1987; 14:451-69.
54. Lorincz A. Detection of human papillomavirus DNA without amplifications: prospects for clinical utility. IARC Sei Publ 1992; 119:135-5.
55. Stoler MH, Broker TR. In situ hybridization detection of human papillomavirus DNAs and messenger RNAs in genital condylomas and a cervical carcinoma. Hum Pathol 1986;17:1250-8.
56. Stoler MH. In situ hybridization: a research technique or routine diagnostic test? [Review] Arch Pathol Lab Med 1993;! 17:47881.
57. Bergeron C, Barrasso R, Beaudenon S, Flamant P, Croissant O, Orth G. Human papillomavirus'es associated with cervical intraepithelial neoplasia: great diversity and distinct distribution in low-grade and high-grade lesions. Am J Surg Pathol 1992;16: 641-9.
58. Kurman RJ, Norris HJ, Wilkinson EJ. Tumors of the Cervix, Vagina ami Vulva. 3rd ed. Washington, DC: Armed Forces Institute of Pathology; 1990.
59. Duggan MA, Benoît JL, McGregor SE, Nation JG, Inoue M, Stuart GC. The human papillomavirus status of 114 endocervical adenocarcinoma cases by dot blot hybridization [see Comments]. Hum Pathol 1993;24:121-5.
60. Farnsworth A, Laverty C, Stoler MH. Human papillomavirus messenger RNA expression in adenocarcinoma in situ of the uterine cervix. Int J Gynecol Pathol 1989;8:321-30.
61. Tase T, Sato S, Wada Y, Yajima A, Okagaki T. Prevalence of human papillomavirus type 18 DNA in adenocarcinoma and adenosquamous carcinoma of the uterine cervix occurring in Japan. Tohoku J Exp Med 1988:156:47-53.
62. Stoler MH, Mills SE, Gerseil DJ, Walker AN. Small-cell neuroendocrine carcinoma of the cervix: a human papillomavirus type 18-associated cancer. Am J Surg Palhol 1991;15:28-32.
63. Campion MJ, McCance DJ, Cuzick J, Singer A. Progressive potential of mild cervical atypia: prospective cytological, colposcopic, and virological study. Lancet 1986;2:237-JO.
64. Kiviat NB, Koutsky LA, Critchlow CW, et al. Prevalence and cytologie manifestations of human papilloma virus (HPV) types 6,11,16,18,31,33,35,42,43,44,45,51,52, and 56 among 500 consecutive women. Int J Gynecol Pathol 1992;! 1:197-203.
65. Lutzner MA. Papillomavirus lesions in immunodepression and immunosuppression. Clin Dermatol 1985;3:165-9.
66. Schneider A, de Villiers EM, Schneider V. Multifocal squamous neoplasia of the female genital tract: significance of human papillomavirus infection of the vagina after hysterectomy. Obstet Gynecol 1987;70:294-8.
67. zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Topics Microbiol Immunol 1977;78:1-30.
68. zur Hausen H. Papillomaviruses in human cancer. Cancer 1987; 59:1692-6.
69. Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 1992:23:117-28.
70. Crum CP, Barber S, Symbula M, Snyder K, Saleh AM, Roche JK. Coexpression of the human papillomavirus type 16 E4 and LI open reading frames in early cervical neoplasia. Virology 1990; 178:238-16.
71. Stoler MH, Wolinsky SM, Whitbeck A, Broker TR, Chow LT. Differentiation-linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridization with message-specific RNA probes. Virology 1989;172:331-40.
72. Stoler MH, Whitbeck A, Wolinsky SM, et al. Infectious cycle of human papillomavirus type 11 in human foreskin xenografts in nude mice. J Virol 1990:64:3310-8.
73. Smotkin D, Wettstein FO. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proc Natl Acad Sei USA 1986:83:4680-4.
74. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM. Structural and transcriptional analysis of human papillomavirus type 16 séquences in cervical carcinoma cell lines. J Virol 1987;61:962-71.
75. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 1984;3:1151-7.
76. Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985;314:111-1
77. Yee C, Krishnan HI, Baker CC, Schlegel R, Howley PM. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am J Pathol 1985;! 19:361-6.
78. Schneider-Gadicke A, Schwarz E. Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J 1986;5:2285-92.
79. Land H, Parada LF, Weinberg RA. Cellular oncogenes and multistep carcinogenesis. Science 1983;222:771-8.
80. Matlashewski G, Schneider J, Banks L, Jones N, Murray A, Crawford L. Human papillomavirus type 16 DNA cooperates with activated rats in transforming primary cells. EMBO J 1987; 6:1741-6.
81. Matlashewski G, Osborn K, Banks L, Stanley M, Crawford L. Transformation of primary human fibroblast cells with human papillomavirus type 16 DNA and EJ-ras. Int J Cancer 1988;42: 232-8.
82. Storey A, Pirn D, Murray A, Osborn K, Banks L, Crawford L. Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J 1988:7:1815-20.
83. Storey A, Banks L. Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary mouse cells. Oncogene 1993;8:919-24.
84. Pirisi L, Yasumoto S, Feller M, Doniger J, DiPaolo JA. Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J Virol 1987;61:1061-6.
85. Pirisi L, Batova A, Jenkins GR, Hodam JR, Creek KE. Increased sensitivity of human keratinocytes immortalized by human papillomavirus type 16 DNA to growth control by retinoids. Cancer Res 1992:52:187-93.
86. Woodworth CD, Doniger J, DiPaolo JA. Immortalization of human foreskin keratinocytes by various human papillomavirus DNAs corresponds to their association with cervical carcinoma. J Virol 1989;63:159-64.
87. Woodworth CD, Waggoner S, Barnes W, Stoler MH, DiPaolo JA. Human cervical and foreskin epithelial cells immortalized by human papillomavirus DNAs exhibit dysplastic differentiation in vivo. Cancer Res 1990:50:3709-15.
88. McCance DJ, Kopan R, Fuchs E, Laimins LA. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc Nat! Acad Sei USA 1988;85:7169-73.
89. Laimins LA. The biology of human papillomaviruses: from warts to cancer. Infect Agents Dis 1993;2:74-86.
90. El-Awady MK, Kaplan JB, O'Brien SJ, Burk RD. Molecular analysis of integrated human papillomavirus 16 sequences in the cervical cancer cell line siHa. Virology 1987; 159:389-98.
91. Choo KB, Pan CC, Liu MS, et al. Presence of episomal and integrated human papillomavirus DNA sequences in cervical carcinoma. J Med Virol 1987;21:101-7.
92. Choo KB, Pan CC, Han SH. Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 1987; 161:259-61.
93. Matsukura T, Koi S, Sugase M. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology 1989; 172:63-72.
94. Shirasawa H, Tomita Y, Kubota K, et al. Detection of human papillomavirus type 16 DNA and evidence for integration into the cell DNA in cervical dysplasia. J Gen Virol 1986;67:2011-5.
95. Shirasawa H, Tomita Y, Sekiya S, Takamizawa H, Simizu B. Integration and transcription of human papillomavirus type 16 and 18 sequences in cell lines derived from cervical carcinomas. JGen V/ro/1987;68:583-91.
96. Cullen AP, Reid R, Campion M, Lorincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invaisve cervical neoplasm. J Virol 1991:65:60612.
97. Chin MT, Hirochika R, Hirochika H, Broker TR, Chow LT. Regulation of human papillomavirus type 11 enhancer and E6 promoter by activating and repressing proteins from the E2 open reading frame: functional and biochemical studies. J Virol 1988; 62:2994-3002.
98. Bishop JM. Viral oncogenes. Cell 1985:42:23-38.
99. Goustin AS, Leof EB, Shipley CD, Moses HL. Perspectives in cancer research: growth factors and cancer. Cancer Res 1986;46: 1015-29.
100. Weinberg RA. The actions of oncogenes in the cytoplasm and nucleus. Science 1985:230:770-6.
101. Weinberg RA. The integration of molecular genetics into cancer management. Cancer 1992;70(6 Suppl.):1653-8.
102. Ocadiz R, Sauceda R, Salcedo M, et al. Occurrence of human papillomavirus type 16 DNA sequences and c-myc oncogene alterations in uterine-cervix carcinoma. Arch Invest Med 1989; 20:355-62.
103. Riou GF. Proto-oncogenes and prognosis in early carcinoma of the uterine cervix. Cancer Surv 1988;7:441-56.
104. Riou GF, Bourhis J, Le MG. The c-myc proto-oncogene in invasive carcinomas of the uterine cervix: clinical relevance of overexpression in early stages of the cancer. Anticancer Res 1990; 10: 1225-31.
105. Riou G, Le MG, Favre M, Jeannel D, Bourhis J, Orth G. Human papillomavirus-negative status and c-myc gene overexpression: independent prognostic indicators of distant metastasis for earlystage invasive cervical cancers. J Natl Cancer Inst 1992;84: 1525-6.
106. Durst M, Kleinheinz A, Hotz M, Gissman L. The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. / Gen Virol 1985;66:1515-22.
107. Durst M, Croce CM, Gissmann L, Schwarz E, Huebner K. Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc Natl Acad Sei USA 1987;84:1070-4.
108. Cannizzaro LA, Durst M, Mendez MJ, Hecht BK, Hecht F. Regional chromosome localization of human papillomavirus integration sites near fragile sites, oncogenes, and cancer chromosome breakpoints. Cancer Genet Cytogene 1988;33:93-8.
109. Stanbridge EJ, Der CJ, Doerson CJ, et al. Human cell hybrids: analysis of transformation and tumorigenicity. Science 1982;215: 252-9.
110. Bosch FX, Schwarz E, Boukamp P, Fusenig NE, Bartsch D, zur Hausen H. Suppression in vivo of human papillomavirus type 18 E6-E7 gene expression in nontumorigenic HeLa X fibroblast hybrid cells. J Virol 1990;64:4743-54.
111. Bosch FX, Durst M, Schwarz E, Boukamp P, Fusenig NE, zur Hausen H. The early genes E6 and E7 of cancer associated human papilloma viruses as targets of tumor suppression? Behring Inst Mitt 1991:89:108-21.
112. Lee W-H, Bookstein R, Hong F, Young L-J, Shew J-Y, Lee EY-HP. Human retinoblastoma gene: cloning, identification and sequence. Science 1987:235:1394-9
113. Lee W-H, Shew J-Y, Hong FD, et al. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 1987:329:642-5.
114. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993;73:499-511.
115. Cryns VL, Thor A, Xu H-J, et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 1994:330:757-61.
116. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993;73:487-97.
117. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989;63:4417-21.
118. Phelps WC, Yee CL, Munger K, Howley PM. Functional and sequence similarities between HPV16 E7 and adenovirus El A. Curr Microbiol Immunol 1989;144:153-66.
119. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
120. Munger K, Werness B A, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989:8:4099-105.
121. Howley PM, Munger K, Werness B A, Phelps WC, Schlegel R. Molecular mechanisms of transformation by the human papillomaviruses. lut Sym Princess Takamatsu Cancer Research Fund 1989:20:199-206.
122. Phelps WC, Yee CL, Munger K, Howley PM. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus El A. Cell 1988:53:539-47.
123. Scheffner M, Werness B A, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:112936.
124. Werness B A, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990:248:76-9.
125. Werness B A, Munger K, Howley PM. Role of the human papillomavirus oncoproteins in transformation and carcinogenic progression. Important Adv Oncol 199I;1991:3-18.
126. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991:10:4129-35.
127. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc NatlAcadSci USA 1991:88:5523-7.
128. Munger K, Scheffner M, Huibregtse JM, Howley PM. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 1992;12:197-217.
129. Scheffner M, Takahashi T, Huibregtse JM, Minna JD, Howley PM. Interaction of the human papillomavirus type-16 E6 oncoprotein with wild-type and mutant human p53 proteins. J Virol 1992:66:5100-5.
130. Crook T, Wrede D, Vousden KH. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 1991;6: 873-5.
131. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours [see Comments]. Lancet 1992:339:1070-3.
132. Fujita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res 1992; 52:5323-8.
133. Kessis TD, Slebos RJ, Han SM, et al. p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am J Palhol 1993;143:1398-105.
134. Lechner MS, Laimins LA. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 1994;68:4262-73.
135. Stoler MH. The biology of papillomaviruses. Pathol Case Rev 1997:2:1-13.
136. Dollard SC, Wilson JL, Demeter LM, et al. Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. Genes Dev 1992;6:1131-42.
137. Demeter LM, Stoler MH, Sobel ME, Broker TR, Chow LT. Expression of high-affinity laminin receptor mRNA correlates with cell proliferation rather than invasion in human papillomavirusassociated cervical neoplasms. Cancer Res 1992;52:1561-7.
138. Demeter LM, Stoler MH, Broker TR, Chow LT. Induction of proliferating cell nuclear antigen in differentiated keratinocytes of human papillomavirus-infected lesions. Hum Pathol 1994;25: 343-8.
139. Higgins GD, Davy M, Roder D, Uzelin DM, Phillips GE, Burrell CJ. Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA. Lancet 1991;338: 910-3.
140. Richart RM, Masood S, Syrjanen KJ, et al. Human papillomavirus. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial. Ada Cylol 1998;42:50-8.
141. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group [see Comments]. J Natl Cancer Inst 1995;87:796-802.
142. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9.
143. Coutlee F, Mayrand MH, Provencher D, Franco E. The future of HPV testing in clinical laboratories and applied virology research, din Diagn Virol 1997;8:123-41.
144. Clavel C, Masure M, Putaud I, et al. Hybrid capture II, a new sensitive test for human papillomavirus detection: comparison with hybrid capture I and PCR results in cervical lesions. / din Pathol 1998;51:737-tO.
145. Clavel C, Bory JP, Rihet S, et al. Comparative analysis of human papillomavirus detection by hybrid capture assay and routine cytologie screening to detect high-grade cervical lesions. Int J Cancer 1998:75:525-8.
146. Jenkins D, Sherlaw-Johnson C, Gallivan S. Can papilloma virus testing be used to improve cervical cancer screening? Int J Cancer 1996;65:768-73.
147. Schneider A. Virologie screening. Eur J Obstet Gynecol Reprod Biol 1996;65:61-3.
148. Schiffman MH, Schatzkin A. Test reliability is critically important to molecular epidemiology: an example from studies of human papillomavirus infection and cervical neoplasia [see Comments]. Cancer Res 1994;54(7 Suppl):1944s-7s.
149. Sherman ME, Schiffman MH, Lorincz AT, et al. Cervical specimens collected in liquid buffer are suitable for both cytologie screening and ancillary human papillomavirus testing. Cancer 1997:81:89-97.
150. Sherman ME, Mendoza M, Lee KR, et al. Performance of liquidbased, thin-layer cervical cytology: correlation with reference diagnoses and human papillomavirus testing. Mod Pathol 1998;! 1: 837-43.
151. Peyton CL, Schiffman M, Lorincz AT, et al. Comparison of PCRand hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies [published erratum appears in J Clin Microbiol 1999:37:478], J Clin Microbiol 1998;36:3248-54.
152. Cope JU, Hildesheim A, Schiffman MH, et al. Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens. J Clin Microbiol 1997; 35:2262-5.
153. Lorincz AT. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. J Obst Gynaecol Res 1996;22:629-36.
154. Lorincz AT. Molecular methods for the detection of human papillomavirus infection. Obst Gynecol Clin North Am 1996;23:70730.
155. Walboomers JM, Husman AM, Snijders PJ, et al. Human papillomavirus in false negative archival cervical smears: implications for screening for cervical cancer. J Clin Pathol 1995;48: 728-32.
156. van Ballegooijen M, van den Akker-van Marie ME, Warmerdam PG, Meijer CJ, Walboomers JM, Habbema JD. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. Br J Cancer 1997;76:651-7.
157. Jacobs MV, Snijders PJ, van den Brûle AJ, Heimerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997:35:791-5.
158. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results [see Comments]. JAMA 1999;281:1605-10.
159. Frazer IH. Immunology of papillomavirus infection. Curr Opin Immunol 1996;8:484-91.
160. Gross G. Therapy of human Papillomavirus infection and associated epithelial tumors. Intervirology 1997;40:368-77.
161. Hines JF, Ghim Si, Jenson AB. Prospects for human papillomavirus vaccine development: emerging HPV vaccines. Curr Opin Obstet Gynecol 1998:10:15-9.
162. Lowy DR, Schiller JT. Papillomaviruses and cervical cancer: pathogenesis and vaccine development. J Natl Cancer Inst Monogr 1998:23:27-30.
163. Lowy DR, Schiller JT. Papillomaviruses: prophylactic vaccine prospects. Biochim Biophys Acta 1999;1423:Ml-8.
164. McNeil C. HPV vaccines for cervical cancer move toward clinic, encounter social issues [News]. J Natl Cancer Inst 1997;89: 1664-6.
165. McNeil C. HPV vaccine treatment trials proliferate, diversify [News]. J Natl Cancer Inst 1997;89:280-1.
166. Sherman ME, Schiffman MH, Strickler H, Hildesheim A. Prospect for a prophylactic HPV vaccine: rational and future implications for cervical screening. Diag Cytopathol 1998;18:5-9.
167. Steller MA, Schiller JT. Human papillomavirus immunology and vaccine prospects. J Natl Cancer Inst Monogr 1996:145-8.